MILES' TRASYLOL FOR CORONARY BYPASS BLOOD-LOSS PREVENTION/REDUCTION "RESERVED FOR HIGH-RISK PATIENTS," FDA SUGGESTS; PROTEASE INHIBITOR APPROVED DEC. 29
Miles' Trasylol (aprotinin), indicated for use in the reduction or prevention of blood loss in patients undergoing coronary artery bypass surgery, should be "reserved for high-risk patients," FDA suggested in a Dec. 30 press release. The agency explained that "severe allergic reactions can result from using [Trasylol] more than once in a patient." In addition, "kidney toxicity was also a problem in some patients in the [clinical] trials," FDA added.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth